fasudil has been researched along with Hyperplasia in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil is an inhibitor of protein kinases, including myosin light chain kinase and Rho associated kinase, thereby inhibiting myosin phosphorylation, and it has been clinically used to prevent vasospasm following subarachnoid hemorrage." | 5.30 | The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. ( Fukui, R; Hoshiga, M; Ii, M; Ishihara, T; Kohbayashi, E; Nakakoji, T; Negoro, N; Nishiguchi, F; Ohsawa, N; Sasaki, Y; Seto, M; Shibata, N, 1999) |
| "To investigate the effects of Rho-kinase inhibitor--fasudil hydrochloride hydrate on vein graft intimal hyperplasia in vivo." | 3.75 | [Experimental study on rho-kinase inhibitor by intravenous injection inhibiting intimal hyperplasia in vein grafts]. ( Guo, M; Ma, L; Pan, J; Yao, S; Yu, X; Zheng, Z, 2009) |
| "Fasudil treatment had favorable effects on wall mass, inhibiting neointimal (P =." | 1.32 | Differential effects of Rho-kinase inhibition on artery wall mass and remodeling. ( Edwards, MS; English, WP; Geary, RL; Li, J; Pearce, JD, 2004) |
| "Fasudil is an inhibitor of protein kinases, including myosin light chain kinase and Rho associated kinase, thereby inhibiting myosin phosphorylation, and it has been clinically used to prevent vasospasm following subarachnoid hemorrage." | 1.30 | The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. ( Fukui, R; Hoshiga, M; Ii, M; Ishihara, T; Kohbayashi, E; Nakakoji, T; Negoro, N; Nishiguchi, F; Ohsawa, N; Sasaki, Y; Seto, M; Shibata, N, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugimoto, M | 1 |
| Yamanouchi, D | 1 |
| Komori, K | 1 |
| Zheng, Z | 1 |
| Pan, J | 1 |
| Ma, L | 1 |
| Yu, X | 1 |
| Guo, M | 1 |
| Yao, S | 1 |
| Pearce, JD | 1 |
| Li, J | 1 |
| Edwards, MS | 1 |
| English, WP | 1 |
| Geary, RL | 1 |
| Seto, M | 2 |
| Shindo, K | 1 |
| Ito, K | 1 |
| Sasaki, Y | 2 |
| Negoro, N | 1 |
| Hoshiga, M | 1 |
| Kohbayashi, E | 1 |
| Ii, M | 1 |
| Fukui, R | 1 |
| Shibata, N | 1 |
| Nakakoji, T | 1 |
| Nishiguchi, F | 1 |
| Ishihara, T | 1 |
| Ohsawa, N | 1 |
1 review available for fasudil and Hyperplasia
| Article | Year |
|---|---|
Therapeutic approach against intimal hyperplasia of vein grafts through endothelial nitric oxide synthase/nitric oxide (eNOS/NO) and the Rho/Rho-kinase pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic beta-Antagonists; Animals; Arginine; Cell | 2009 |
4 other studies available for fasudil and Hyperplasia
| Article | Year |
|---|---|
[Experimental study on rho-kinase inhibitor by intravenous injection inhibiting intimal hyperplasia in vein grafts].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Female; Graft Survival; Hyperplasia; Male; P | 2009 |
Differential effects of Rho-kinase inhibition on artery wall mass and remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Carotid Arteries; Cells, Cultured; Co | 2004 |
Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Carotid Arteries; Hyperplasia; In V | 1995 |
The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Actins; Animals; Aorta; Carotid A | 1999 |